Cargando…

Recurrence patterns in patients with high-grade glioma following temozolomide-based chemoradiotherapy

There is currently no consensus regarding the optimal radiation volume for high-grade glioma (HGG). The brain volume irradiated is associated with the extent of radiation neurotoxicity. When reducing the treatment volume, the risk of geographic tumor miss should be considered. In such cases, the rec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Xiaofeng, Liao, Xiaofang, Zhang, Bicheng, He, Huijuan, Shui, Yongjie, Xu, Wenhong, Jiang, Chaogen, Shen, Li, Wei, Qichun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2016
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4950878/ https://www.ncbi.nlm.nih.gov/pubmed/27446566 http://dx.doi.org/10.3892/mco.2016.936

Ejemplares similares

The Definition and Delineation of the Target Area of Radiotherapy Based on the Recurrence Pattern of Glioblastoma After Temozolomide Chemoradiotherapy
por: Zheng, Lin, et al.
Publicado: (2021)

Temozolomide and Reirradiation in Recurrent Grade II Brain Glioma
por: Osman, Mohammed A
Publicado: (2014)

Postoperative recurrent patterns of gallbladder cancer: possible implications for adjuvant therapy
por: Yuan, Zhijun, et al.
Publicado: (2022)

Observation of the delineation of the target volume of radiotherapy in adult-type diffuse gliomas after temozolomide-based chemoradiotherapy: analysis of recurrence patterns and predictive factors
por: Liu, Hongbo, et al.
Publicado: (2023)

Depatux-M and temozolomide in advanced high-grade glioma
por: Hirsch, Sophie, et al.
Publicado: (2020)

Anlotinib Alone or in Combination With Temozolomide in the Treatment of Recurrent High-Grade Glioma: A Retrospective Analysis
por: Yang, Qunying, et al.
Publicado: (2021)

Efficacy of apatinib combined with temozolomide in the treatment of recurrent high‑grade glioma: A meta‑analysis
por: Li, Guanglie, et al.
Publicado: (2023)

Temozolomide Chemotherapy in Patients with Recurrent Malignant Gliomas
por: Yang, Seung-Ho, et al.
Publicado: (2006)

Comparison of long-term survival between temozolomide-based chemoradiotherapy and radiotherapy alone for patients with low-grade gliomas after surgical resection
por: Gai, Xiu-juan, et al.
Publicado: (2016)

Intrinsic immune evasion patterns predict temozolomide sensitivity and immunotherapy response in lower-grade gliomas
por: Tu, Zewei, et al.
Publicado: (2022)

Dynamic MRI follow-up of radiation encephalopathy in the temporal lobe following nasopharyngeal carcinoma radiotherapy
por: Zhou, Xiaofeng, et al.
Publicado: (2017)

Patterns of recurrence after curative D2 resection for gastric cancer: Implications for postoperative radiotherapy
por: Xu, Jing, et al.
Publicado: (2020)

Transcriptional Patterns of Lower-Grade Glioma Patients with Distinct Ferroptosis Levels, Immunotherapy Response, and Temozolomide Sensitivity
por: Tu, Zewei, et al.
Publicado: (2022)

Temozolomide in paediatric high-grade glioma: a key for combination therapy?
por: Verschuur, A C, et al.
Publicado: (2004)

Impact of Including Peritumoral Edema in Radiotherapy Target Volume on Patterns of Failure in Glioblastoma following Temozolomide-based Chemoradiotherapy
por: Choi, Seo Hee, et al.
Publicado: (2017)

Temozolomide in malignant glioma
por: Dresemann, Gregor
Publicado: (2010)

Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy
por: Murphy, P S, et al.
Publicado: (2004)

Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea
por: Kim, Byung Sup, et al.
Publicado: (2017)

The Effect of Chemoradiotherapy with SRC Tyrosine Kinase Inhibitor, PP2 and Temozolomide on Malignant Glioma Cells In Vitro and In Vivo
por: Eom, Keun-Yong, et al.
Publicado: (2016)

Imaging-Based Patterns of Failure following Re-Irradiation for Recurrent/Progressive High-Grade Glioma †
por: Datta, Debanjali, et al.
Publicado: (2023)

Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide
por: Koekkoek, Johan A. F., et al.
Publicado: (2015)

Bevacizumab in temozolomide refractory high-grade gliomas: single-centre experience and review of the literature
por: Jeck, Jennifer, et al.
Publicado: (2018)

Radiation and chemotherapy for high‐risk lower grade gliomas: Choosing between temozolomide and PCV
por: McDuff, Susan G. R., et al.
Publicado: (2019)

Phase I Study of High-Dose l-Methylfolate in Combination with Temozolomide and Bevacizumab in Recurrent IDH Wild-Type High-Grade Glioma
por: Salas, Lucas A., et al.
Publicado: (2022)

Initial and cumulative recurrence patterns of glioblastoma after temozolomide-based chemoradiotherapy and salvage treatment: a retrospective cohort study in a single institution
por: Ogura, Kengo, et al.
Publicado: (2013)

A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma
por: Dinnes, J, et al.
Publicado: (2002)

Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas
por: Wong, Eric T., et al.
Publicado: (2016)

Radiomics Signature Based on Support Vector Machines for the Prediction of Pathological Complete Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
por: Li, Chao, et al.
Publicado: (2023)

Factors Associated With Neurocognitive Impairment Following Chemoradiotherapy in Patients With High-Grade Glioma: Results of a Prospective Trial
por: Sharma, Prashasti, et al.
Publicado: (2023)

Predicting the outcome of grade II glioma treated with temozolomide using proton magnetic resonance spectroscopy
por: Guillevin, R, et al.
Publicado: (2011)

Efficacy and safety of long-term therapy for high-grade glioma with temozolomide: A meta-analysis
por: Xu, Weilin, et al.
Publicado: (2017)

ACT-18 SHOULD THE DOSE OF TEMOZOLOMIDE BE DECREASED FOR PATIENTS WITH HIGH-GRADE GLIOMAS WHO ARE ON HEMODIALYSIS?
por: Muto, Jun, et al.
Publicado: (2019)

Nidogen-1 expression is associated with overall survival and temozolomide sensitivity in low-grade glioma patients
por: Zhang, Baiwei, et al.
Publicado: (2021)

Long-term adjuvant administration of temozolomide impacts serum ions concentration in high-grade glioma
por: Zhong, Liyun, et al.
Publicado: (2022)

A gene signature predicting prognosis of patients with lower-grade gliomas receiving temozolomide therapy
por: Wan, Yanzhi, et al.
Publicado: (2023)

Receptor tyrosine kinase expression in high-grade gliomas before and after chemoradiotherapy
por: Wang, Kuanyu, et al.
Publicado: (2019)

Glioma SOX2 expression decreased after adjuvant therapy
por: Yu, Wei, et al.
Publicado: (2019)

Narrow-Margin Hepatectomy Resulted in Higher Recurrence and Lower Overall Survival for R0 Resection Hepatocellular Carcinoma
por: Liu, Lihong, et al.
Publicado: (2021)

Prediction of Response to Temozolomide in Low‐Grade Glioma Patients Based on Tumor Size Dynamics and Genetic Characteristics
por: Mazzocco, P, et al.
Publicado: (2015)

Temozolomide with Radiation Therapy in High Grade Brain Gliomas: Pharmaceuticals Considerations and Efficacy; A Review Article
por: Koukourakis, Georgios V., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_enftlukkesf0ljbd6hcckag3rm